334 related articles for article (PubMed ID: 35639152)
41. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.
Tokunaga T; Shimada K; Yamamoto K; Chihara D; Ichihashi T; Oshima R; Tanimoto M; Iwasaki T; Isoda A; Sakai A; Kobayashi H; Kitamura K; Matsue K; Taniwaki M; Tamashima S; Saburi Y; Masunari T; Naoe T; Nakamura S; Kinoshita T
Blood; 2012 Mar; 119(12):2837-43. PubMed ID: 22308294
[TBL] [Abstract][Full Text] [Related]
42. Angioimmunoblastic T-cell lymphoma: treatment strategies and prognostic factors from a retrospective multicenter study in China.
Zhang C; Mi L; Wu M; Liu W; Ma H; Ren J; Zhao L; Wang X; Song Y; Zhu J
Leuk Lymphoma; 2022 May; 63(5):1152-1159. PubMed ID: 34957894
[TBL] [Abstract][Full Text] [Related]
43. [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].
Tang XF; Li GD; Li YL; Liang DN; Xia T; Zhou JY; Yao YQ; Wu WQ; Wang ZG; Yang YH; Tang XB; Bai YQ; Ding Q
Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):224-30. PubMed ID: 19575892
[TBL] [Abstract][Full Text] [Related]
44. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
[No Abstract] [Full Text] [Related]
45. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
Advani RH; Skrypets T; Civallero M; Spinner MA; Manni M; Kim WS; Shustov AR; Horwitz SM; Hitz F; Cabrera ME; Dlouhy I; Vassallo J; Pileri SA; Inghirami G; Montoto S; Vitolo U; Radford J; Vose JM; Federico M
Blood; 2021 Jul; 138(3):213-220. PubMed ID: 34292324
[TBL] [Abstract][Full Text] [Related]
46. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
Lim ST; Hee SW; Quek R; Lim LC; Yap SP; Loong EL; Sng I; Tan LH; Ang MK; Ngeow J; Tham CK; Ngo L; Tan MH; Tao M
Eur J Haematol; 2008 Jan; 80(1):55-60. PubMed ID: 18028433
[TBL] [Abstract][Full Text] [Related]
47. An Isolated Mesenteric Presentation of a Nodal Peripheral T Cell Lymphoma with T Follicular Helper Cell Phenotype.
Keogh A; Lynott F; Papanicolau-Sengos A; Mohammed Nur M; Spillane A; Quinn F; ElHassadi E; Jaffe ES; Flavin R
Hematol Rep; 2022 Nov; 14(4):335-341. PubMed ID: 36412627
[TBL] [Abstract][Full Text] [Related]
48. Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases.
Zhan HQ; Li XQ; Zhu XZ; Lu HF; Zhou XY; Chen Y
J Clin Pathol; 2011 Apr; 64(4):319-24. PubMed ID: 21330314
[TBL] [Abstract][Full Text] [Related]
49. Human Germinal Center-associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma.
Koo M; Zhang J; Tan B; Kurzer J; Gratzinger D; Zhao S; Suarez C; Lossos IS; Warnke RA; Natkunam Y
Am J Surg Pathol; 2022 May; 46(5):643-654. PubMed ID: 34907996
[TBL] [Abstract][Full Text] [Related]
50. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification.
Arrowsmith ER; Macon WR; Kinney MC; Stein RS; Goodman SA; Morgan DS; Flexner JM; Cousar JB; Jagasia MH; McCurley TL; Greer JP
Leuk Lymphoma; 2003 Feb; 44(2):241-9. PubMed ID: 12688340
[TBL] [Abstract][Full Text] [Related]
51. Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis.
Dobson R; Du PY; Rásó-Barnett L; Yao WQ; Chen Z; Casa C; Ei-Daly H; Farkas L; Soilleux E; Wright P; Grant JW; Rodriguez-Justo M; Follows GA; Rashed H; Fabre M; Baxter EJ; Vassiliou G; Wotherspoon A; Attygalle AD; Liu H; Du MQ
Haematologica; 2022 Feb; 107(2):489-499. PubMed ID: 33567811
[TBL] [Abstract][Full Text] [Related]
52. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
[TBL] [Abstract][Full Text] [Related]
53. 25-Hydroxy vitamin D deficiency is an inferior predictor of peripheral T-cell lymphomas.
Shen HR; Tang J; Li WY; Liang JH; Li Y; Wu JZ; Wang L; Li JY; Gao R; Yin H; Xu W
Ann Hematol; 2024 Feb; 103(2):565-574. PubMed ID: 37951853
[TBL] [Abstract][Full Text] [Related]
54. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China.
Wei C; Li W; Qin L; Liu S; Xue C; Ren K; Zhang Z; Liu C; Bao F; Zhang H; Zhou H; Li Z; Wu H; Zou L; Liu L; Jing H; Zhang W
Cancer Med; 2023 Feb; 12(4):3987-3998. PubMed ID: 36106610
[TBL] [Abstract][Full Text] [Related]
56. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients.
de Pádua Covas Lage LA; Barreto GC; Culler HF; Cavalcante JB; de Oliveira Alves LB; Nardinelli L; Bendit I; Zerbini MCN; Rocha V; Pereira J
Cancer Biomark; 2022; 35(2):179-191. PubMed ID: 36093687
[TBL] [Abstract][Full Text] [Related]
57. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
Meeuwes FO; Brink M; Plattel W; Van der Poel MWM; Kersten MJ; Wondergem M; Böhmer L; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Neelis KJ; Crijns APG; Daniëls LA; Snijders TJF; Vermaat JSP; Huls GA; Nijland M
Haematologica; 2024 Apr; 109(4):1163-1170. PubMed ID: 37794805
[TBL] [Abstract][Full Text] [Related]
58. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.
Lemonnier F; Couronné L; Parrens M; Jaïs JP; Travert M; Lamant L; Tournillac O; Rousset T; Fabiani B; Cairns RA; Mak T; Bastard C; Bernard OA; de Leval L; Gaulard P
Blood; 2012 Aug; 120(7):1466-9. PubMed ID: 22760778
[TBL] [Abstract][Full Text] [Related]
59. A novel prognostic model for angioimmunoblastic T-cell lymphoma: A retrospective study of 55 cases.
Sun J; He S; Cen H; Zhou D; Li Z; Wang MY; Ke Q; Guo BP; Liao CC; Rong C; Zhong DN; Tan XH
J Int Med Res; 2021 May; 49(5):3000605211013274. PubMed ID: 34034561
[TBL] [Abstract][Full Text] [Related]
60. Angioimmunoblastic T-Cell Lymphoma.
Yabe M; Dogan A; Horwitz SM; Moskowitz AJ
Cancer Treat Res; 2019; 176():99-126. PubMed ID: 30596215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
